文献速递炎症性肠病

英夫利西单抗双次转换至生物类似药CT-P13和SB2的12个月前瞻性队列研究结局

Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2021-03-01

本研究为前瞻性队列研究,纳入158例接受CT-P13维持治疗的炎症性肠病患者,转换为SB2并随访54周。结果显示药物留存率高(94.9%),10.8%患者出现失应答,临床活动评分、疲劳、生物学活性及药代动力学参数无变化,安全性与已知英夫利西单抗一致,患者信念无改变。

要点

  • 双次转换后54周药物留存率达94.9%,失应答率10.8%。
  • 转换后临床活动评分、疲劳、生物学活性及药代动力学参数稳定。
  • 患者对药物信念无变化,关注点仍为有效性和安全性。

核心结论

  • 从原研英夫利西单抗双次转换至CT-P13再至SB2未损害患者信念,抗TNF治疗的有效性、免疫原性和安全性在54周随访中保持稳定。

研究设计与样本

  • 前瞻性队列研究,纳入158例接受CT-P13维持治疗的炎症性肠病患者,转换为SB2并随访54周,按既往是否从原研药转换为CT-P13分为双次转换组和单次转换组。

主要发现

  • 54周药物留存率为94.9%。
  • 17例(10.8%)患者出现对SB2的失应答,其中10例通过剂量优化继续治疗。
  • 转换后临床活动评分、疲劳、生物学活性及药代动力学参数无变化。
  • 安全性与当前对英夫利西单抗的认知一致。
  • 根据信念关于药物问卷,患者观点在转换后未改变,主要关注有效性和安全性而非分子差异或社会经济收益,双次与单次转换组间无差异。

临床怎么用

  • 支持在炎症性肠病患者中从原研英夫利西单抗双次转换至生物类似药CT-P13和SB2后维持治疗的有效性和安全性。
  • 转换后患者信念稳定,临床关注点应集中于有效性和安全性监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are few data regarding multiple switching from the originator Infliximab to its biosimilars. AIM: To assess outcomes and patient perspectives in a prospective manner after double switching from Infliximab to the biosimilars CT-P13 and SB2. METHODS: A total of 158 consecutive patients with inflammatory bowel disease (IBD) receiving CT-P13 maintenance therapy were switched to SB2 and followed for 54 weeks. Patients were stratified according to previous switch from the originator Infliximab to CT-P13 (double switch group) or not (single switch group). RESULTS: The drug persistence was high (94.9%) after 54 weeks. In total, 17 (10.8%) patients experienced loss of response to SB2, including 10 patients who were managed through dose optimisation and continued treatment. No changes were observed in clinical activity scores, fatigue, biological activity and pharmacokinetical parameters after the switch. The safety profile was in line with the current knowledge of Infliximab. According to the Beliefs about Medicines Questionnaire, the patients' perspectives did not change after switching from CT-P13 to SB2. The primary patient concerns remained after the switch, which were focused on effectiveness and safety rather than on the molecular differences between originator and biosimilars or socioeconomic benefits. There were also no differences in the concerns and beliefs between the double and single switch groups. CONCLUSION: Double switching from the originator Infliximab to CT-P13 and then to SB2 was not associated with an impairment in patient beliefs, while the effectiveness, immunogeniity and safety of anti-TNF therapy remained stable after 54 weeks of follow-up.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Trystram N, Abitbol V, Tannoury J, et al. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Aliment Pharmacol Ther. 2021. PMID: 33647174. doi:10.1111/apt.16312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。